Qiagen NV

NYSE:QGEN   3:59:59 PM EDT
48.43
-0.05 (-0.10%)
4:00:00 PM EDT: $48.42 -0.01 (-0.02%)
Products, Regulatory

Qiagen, Denovo Biopharma Partner To Develop Companion Diagnostic Test

Published: 12/09/2021 06:38 GMT
Qiagen NV (QGEN) - Qiagen and Denovo Biopharma Partner to Develop Companion Diagnostic Test for Treatment of Diffuse Large B-cell Lymphoma (dlbcl).
Qiagen's Blood-based Test Will Help to Identify Patients With Diffuse Large B-cell Lymphoma (dlbcl) Likely to Respond to Denovo's New Investigational Cancer Treatment Db102tm.
Partners Seek FDA Premarket Approval (pma) of Companion Diagnostic Test in Tandem With New Drug Application (nda) Approval.